-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$118.84607.8% Upside
Recent Analyst Forecasts and Stock Ratings
Intellia Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. has been rated by research analysts at Robert W. Baird, RBC Capital, Stifel Nicolaus, BMO Capital, Cantor Fitzgerald, Wells Fargo in the past 90 days.